> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CSL Behring’s Zemaira OK’d for Larger Vials
- URL: https://www.fdaweb.com/csl-behrings-zemaira-okd-for-larger-vials/
- Published: 2019-04-26T12:00:00.000Z
- Updated: 2026-09-15T01:22:56.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5143970

FDA has approved CSL Behring’s four- and five-gram vial sizes for Zemaira \[alpha1-proteinase inhibitor (human)\], its therapy for treating Alpha 1 Antitrypsin Deficiency. Previously, Zemaira was available only in a one-gram vial, and the new sizes reduces the number of vials necessary for reconstitution, the company says. The natural Alpha 1 protein is derived from human plasma, which CSL Behring says has been shown to raise and maintain serum levels of alpha 1 antitrypsin (AAT) protein in patients. Alpha 1 Antitrypsin Deficiency is a hereditary condition that can severely affect a patient’s lung function, it says. The condition is marked by a low level or absence of AAT, a natural protein that inhibits neutrophil elastase which prevents destruction of lung tissue.